Schumann K M, Massarrat S
Department of Gastroenterology and Metabolic Diseases, Klinikum of Philipps-University, Marburg, West Germany.
Hepatogastroenterology. 1991 Dec;38 Suppl 1:33-6.
The levels of total pepsin activity and pepsinogen I in sera were first studied in 10 healthy volunteers undergoing stimulation of gastric acid secretion at random on 4 different days with a) a maximum dose (6 micrograms/kg) of pentagastrin, b) ranitidine injection 5 minutes before maximal pentagastrin stimulation, c) ranitidine injection 1 hr before maximal pentagastrin stimulation, or d) sham feeding. In a further 10 healthy volunteers the levels of total pepsin activity and pepsinogen I were studied over 5 days by short-term oral intake of ranitidine. The total pepsin activity and pepsinogen I increased significantly in the sera after maximum-dose pentagastrin, but not after sham feeding. The increase could be completely prevented by ranitidine given only 1 hour before pentagastrin stimulation. The total pepsin activity and pepsinogen I decreased significantly after brief oral intake of ranitidine. It can be concluded that the measurement of total pepsin activity and pepsinogen I in the sera could serve as a rough parameter for testing the effectiveness of potential agents inhibiting gastric secretion.
首先,在10名健康志愿者中研究了血清中总胃蛋白酶活性和胃蛋白酶原I的水平。这10名志愿者在4个不同日期随机接受胃酸分泌刺激,刺激方式如下:a)五肽胃泌素最大剂量(6微克/千克);b)在最大剂量五肽胃泌素刺激前5分钟注射雷尼替丁;c)在最大剂量五肽胃泌素刺激前1小时注射雷尼替丁;或d)假饲。在另外10名健康志愿者中,通过短期口服雷尼替丁,对总胃蛋白酶活性和胃蛋白酶原I的水平进行了为期5天的研究。血清中总胃蛋白酶活性和胃蛋白酶原I在五肽胃泌素最大剂量刺激后显著增加,但假饲后未增加。仅在五肽胃泌素刺激前1小时给予雷尼替丁,可完全阻止这种增加。短期口服雷尼替丁后,总胃蛋白酶活性和胃蛋白酶原I显著降低。可以得出结论,血清中总胃蛋白酶活性和胃蛋白酶原I的测定可作为检测潜在胃酸分泌抑制药物有效性的一个粗略参数。